You have 9 free searches left this month | to do more

palbociclib

Palbociclib is a drug used to treat Breast Cancer, Breast Neoplasms, HER2/Neu Negative, and other conditions. Palbociclib is being actively studied in 131 studies and prior, has been studied in 31.

Top SponsorsTop SitesTop Investigators
PfizerDana-Farber Cancer InstituteGeoffrey Shapiro, MD, PhD
Dana-Farber Cancer InstituteWashington University School of MedicineErica Mayer, MD, MPH
National Cancer Institute (NCI)Beth Israel Deaconess Medical CenterYeon Hee Park
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
P
Palbociclib Continuation Study for Participants Continuing From Pfizer-sponsored Palbociclib Clinical Studies
Not yet recruiting
  • Breast Cancer
  • Head and Neck Cancer
  • Palbociclib
  • +3 more
  • (no location specified)
2022-01-26
Jan 26, 2022
S
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
Active, not recruiting
  • Metastatic Breast Cancer
  • Pittsburgh, Pennsylvania
    Magee-Womens Hospital UPMC
2021-07-22
Jul 22, 2021
W
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Palbociclib
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-02-25
Feb 25, 2022
P
Demographics, Characteristics, Treatment Patterns and Clinical Outcomes of Palbociclib Treated Patients in Israel - 2021
Completed
  • Metastatic Breast Cancer
  • palbociclib
  • Herzliya Pituach, Israel
    Pfizer Pharmaceuticals Israel Ltd.
2022-01-20
Jan 20, 2022
S
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
Recruiting
  • Metastatic Breast Cancer
  • Washington, District of Columbia
  • +4 more
2022-01-10
Jan 10, 2022
F
Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET
Active, not recruiting
  • Metastatic Breast Cancer
  • Palbociclib
  • Shanghai, China
    Fudan University Shanghai Cancer Center
2021-09-13
Sep 13, 2021
F
Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer
Recruiting
  • Estrogen Receptor-positive Breast Cancer
  • HER2-positive Breast Cancer
  • Palbociclib
  • +3 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Hospital
2021-09-29
Sep 29, 2021
A
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period
Recruiting
  • Metastatic Breast Cancer
  • Palbociclib
  • Timisoara, Timiș, Romania
    Asociatia Oncohelp - Centrul de Oncologie Oncohelp
2022-02-15
Feb 15, 2022
M
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
Recruiting
  • Advanced Solid Tumor
  • Houston, Texas
  • +1 more
2022-02-18
Feb 18, 2022
M
Palbociclib In Progressive Brain Metastases
Recruiting
  • Metastatic Malignant Neoplasm to Brain
  • Palbociclib
  • Boston, Massachusetts
  • +1 more
2021-10-25
Oct 25, 2021
B
Avelumab, Palbociclib and Axitinib in Advanced RCC
Not yet recruiting
  • Advanced Clear Cell Renal Cell Carcinoma
  • Boston, Massachusetts
  • +2 more
2021-12-16
Dec 16, 2021
N
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
Active, not recruiting
  • Advanced Lymphoma
  • +4 more
  • Palbociclib
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
U
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
Recruiting
  • Cancer of the Colon
  • +4 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
2022-01-25
Jan 25, 2022
R
Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer
Recruiting
  • Colorectal Carcinoma
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
2021-12-30
Dec 30, 2021
A
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
Recruiting
  • Metastatic Breast Cancer
  • +4 more
  • Palbociclib
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
2021-07-20
Jul 20, 2021
A
Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
Recruiting
  • Female Breast Carcinoma
  • Charlotte, North Carolina
    Levine Cancer Institute
2022-02-21
Feb 21, 2022
D
PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors
Active, not recruiting
  • KRAS Mutant Non-Small Cell Lung Cancer
  • Solid Tumors
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2022-01-18
Jan 18, 2022
U
Palbociclib and FES PET
Active, not recruiting
  • Breast Cancer
  • Palbociclib
  • +2 more
  • Groningen, Netherlands
    University Medical Center Groningen
2021-02-01
Feb 1, 2021
S
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Recruiting
  • Recurrent B Acute Lymphoblastic Leukemia
  • Refractory B Acute Lymphoblastic Leukemia
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
2022-04-07
Apr 7, 2022
T
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
Recruiting
  • Acute Lymphoblastic Leukemia, Pediatric
  • +2 more
  • Palbociclib
  • +3 more
  • Stanford, California
    Lucile Packard Children's Hospital Stanford
2021-09-20
Sep 20, 2021
D
Palbociclib + Ganitumab In Ewing Sarcoma
Active, not recruiting
  • Ewing Sarcoma
  • Ewing's Sarcoma Recurrent
  • Boston, Massachusetts
  • +2 more
2022-03-21
Mar 21, 2022
H
PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer
Recruiting
  • Metastatic Breast Cancer
  • Palbociclib
  • +2 more
  • Johannesburg, South Africa
    Wits Oncology center
2021-07-22
Jul 22, 2021
D
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Recruiting
  • Lung Cancer
  • Boston, Massachusetts
  • +1 more
2022-01-18
Jan 18, 2022
A
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Recruiting
  • Breast Cancer
  • Philadelphia, Pennsylvania
    University of Pennsylvania
2021-07-26
Jul 26, 2021
J
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Active, not recruiting
  • Estrogen Receptor Positive
  • +16 more
  • Biopsy of Breast
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
2021-10-07
Oct 7, 2021